Elevance Health earnings improved in the third quarter of 2026 as adjusted diluted EPS reached $6.99. Operating revenue rose 0.7% to $50.4 billion, while the insurer raised its full-year guidance.
Elevance Health earnings benefit from lower medical costs
Operating revenue increased by $0.4 billion from the prior-year quarter. Higher premium yields, CarelonRx product revenue and service fees offset lower membership in several risk businesses.
The benefit expense ratio declined to 90.6% from 91.3%. A lower ratio means medical claims consumed a smaller share of premium revenue.
Consolidated operating revenue
Q3 2025: $50.0B
Q3 2026: $50.4B
Health Benefits
Q3 2025: $42.3B
Q3 2026: $43.4B
Carelon
Q3 2025: $18.3B
Q3 2026: $19.3B
Source: Elevance Health’s October 21, 2026 results. Prior-year values reflect company-reported changes.
Quarterly operating cash flow reached $1.3 billion, up $0.1 billion. Parent-company cash and investments totaled about $2.4 billion at September 30.
Other recent earnings coverage includes Abbott’s healthcare sales growth, Dime Bank’s margin expansion, and Kroger’s long-term EPS target.
Elevance Health earnings guidance moves higher
Health Benefits revenue rose 3% to $43.4 billion, but medical membership fell by 487,000 to 44.9 million. The decline reflected lower Medicaid, Medicare Advantage and employer risk-based enrollment.
Carelon revenue increased 5% to $19.3 billion. Its operating gain rose 17% to $0.9 billion as specialty pharmacy profitability and risk-based services improved.
Elevance raised full-year GAAP diluted EPS guidance to at least $22.00. Adjusted diluted EPS guidance increased to at least $29.00, while operating cash flow guidance rose to at least $6.5 billion.
The company’s official October 21 earnings release provides the figures and reconciliation details. The announcement date is separate from the quarter ended September 30.



